
US007951382B2 (12) United States Patent (10) Patent No.: US 7,951,382 B2 Gelber et al. (45) Date of Patent: May 31, 2011 (54) METHODS FORTREATMENT OF TYPE 2 WO O3,O14151 A2 2/2003 DABETES WO 2004/084797 A2 10, 2004 WO 2005/055956 6, 2005 (75) Inventors: Cohava Gelber, Nokesville, VA (US); W 38885 33.9 Liping Liu, Manassas, VA (US); Zhidong Xie, Manassas, VA (US); OTHER PUBLICATIONS Pranvera Ikonomi, Manassas, VA (US); Antibody Directory (2006), Antichymotrypsin, 3 pages. John R Simms, Haymarket, VA (US); Belagaje et al. (1979) The Journal of Biochemistry 254:5765-5780. Catherine R Auge, Haymarket, VA (US) Better et al. (1988), Science 240: 1041-1043. Boulianne et al. (1984), Nature 312:643-646. (73) Assignee: American Type Culture Collection, Budde et al. (2005), Combinatorial Chemistry & High Throughput Manassas, VA (US) Screening 8:775-781. Burke et al. (1999), Arch. Intern. Med. 159: 1450-1456. (*) Notice: Subject to any disclaimer, the term of this Cabilly et al. (1984) Proc. Natl. Acad. Sci. USA 81:3273-3277. patent is extended or adjusted under 35 Chater et al. (1986) In: Sixth International Symposium on U.S.C. 154(b) by 0 days. Actinomycetales Biology, Akademiai Kaido, Budapest, Hungary pp. 45-54. (21) Appl. No.: 12/759,072 DeLong et al. (1988) Biometrics 44:837-845. Eddy et al. (2003) Diabetes Care 26:3102-31 10. (22) Filed: Apr. 13, 2010 Eddy et al. (2003) Diabetes Care 26:3093-3101. Glover (1985) ed. DNA Cloning vol. II. pp. 143-238, IRL Press. (65) Prior Publication Data Glover (1985) ed. DNA Cloning vol. II. pp. 45-66, IRL Press. US 2010/O197596 A1 Aug. 5, 2010 Gorman et al. (1982) Proc. Natl. Acad. Sci. USA 79:6777-6781. Griffin et al., (2000) Diabetes Metabolism Research and Reviews, Related U.S. Application Data 16:164-171 Grosschedl et al. (1985) Cell 41:885-897. (60) Division of application No. 12/319,883, filed on Jan. Gryczan (1982), Academic Press, NY. pp. 307-329. 12, 2009, now abandoned, which is a Hanson et al. (2002) Diabetes 51:3120-3127. continuation-in-part of application No. 1 1/901,925, Horvath et al. (2004) Journal of Molecular Evolution 59:488-497. filed on Sep. 18, 2007, now abandoned, which is a Hu et al. (2004) Diabetes 53:693-700. continuation-in-part of application No. Izaki (1978), Jpn. J. Bacteriol. 33:729-742. PCT/US2007/007875, filed on Mar. 28, 2007. John et al. (1986) Reviews of Infectious Diseases 8:693-704. Johnston et al. (1988) Science 203:614-625. (60) Provisional application No. 60/841,717, filed on Sep. Kannel et al. (1976) The American Journal of Cardiology 38:46-51. 1, 2006. Kendall et al. (1987) Journal of Bacteriology 169:4177-4183. Khorana (1979) Science 203:614-625. (51) Int. Cl. Kohler et al. (1975) Nature 256:495-497. A6 IK38/17 (2006.01) Kozbor et al. (1983) Immunology Today 4:72-79. (52) U.S. Cl. ..................................... 424/198.1:530/300 Lathe et al. (1985) J. Molec. Biol. 183: 1-12. Lindström (2003) Diabetes Care 26:725-731. (58) Field of Classification Search ........................ None Liu et al. (1987) The Journal of Immunology 139:3521-3526. See application file for complete search history. Liu et al. (1987) Proc. Natl. Acad. Sci. USA 84:3439-3443. Marks et al. (1993) Bio/Technology 11:1145-1149. (56) References Cited Meigs et al. (2004) JAMA 291: 1978-1986. Miller et al. (1989) Bio/Technology 7:698-704. U.S. PATENT DOCUMENTS Mischak et al. (2004) Clinical Science 107:485-495. 4,230,767 A 10, 1980 Isaka et al. Morrison et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855. 4,233,402 A 11/1980 Maggio et al. Muller (1983) Methods in Enzymology 92:589-601. 4,275,149 A 6, 1981 Litman et al. Neuberger et al. (1985) Nature 314:268-270. 4,376, 110 A 3, 1983 David et al. Nyyssönen et al. (1993) Bio/Technology 11:591-595. 4,522,811 A 6/1985 Eppstein et al. 4,659,678 A 4, 1987 Forrest et al. (Continued) 4,699,880 A 10, 1987 Goldstein 4,727,022 A 2f1988 Skold et al. 5,744,305 A 4, 1998 Fodor et al. Primary Examiner — Ruixiang Li 7,255,988 B2 8, 2007 Halle et al. (74) Attorney, Agent, or Firm — Nixon Peabody LLP 7,648,825 B2 1/2010 Ellis et al. 2004/0224304 A1 11/2004 Berggren (57) ABSTRACT 2007/00597 22 A1 3/2007 Salonen et al. The present invention relates generally to the identification of FOREIGN PATENT DOCUMENTS biological markers associated with an increased risk of devel EP O125O23 11, 1984 oping Diabetes, as well as methods of using such biological EP O171496 2, 1986 markers in diagnosis and prognosis of Diabetes. The biologi EP O173494 3, 1986 EP O1841.87 6, 1986 cal markers of the invention may indicate new targets for EP 1615035 1, 2006 therapy or constitute new therapeutics for the treatment or JP 2003235573 8, 2003 prevention of Diabetes. WO 86/O1533 3, 1986 WO 87,02671 5, 1987 6 Claims, 23 Drawing Sheets US 7,951,382 B2 Page 2 OTHER PUBLICATIONS Sun et al. (1987) Proc. Natl. Acad. Sci. USA 84:214-218. UniProtKB/Swiss-Prot PO100 (1991) Serpina3, 8 pages. O’Marcaigh et al. (1993) Clinical Pediatrics 32:485-491. Okayama et al. (1983) Mol. Cell. Biol. 3:280. UniProtKB/Swiss-Prot Q63556 (1996) Serpina3M, 4 pages. Potter et al. (1984) Proc. Natl. Acad. Sci. USA 81:7161. Velculescu et al. (1995) Science 270:484-487. Sabinet al. (1989) BioTechnology 7:705-709. Wahl et al. (1983) The Journal of Nuclear Medicine 24:316-325. Sahagan et al. (1986) The Journal of Immunology 137: 1066-1074. Weidle et al. (1987) Gene 51:21-29. Shultz (1996) Clinical Interpretation of Laboratory Procedures, pp. Whittle et al. (1987) Protein Engineering 1:499-505. 192-199. Wirth et al. (2002) Proteomics 2: 1445-1451. Stefan et al. (2006) Diabetes Care 29:853-857. Wu et al. (1978) Prog. Nucl. Acid Res. Molec. Biol. 21:101-141. Sternet al. (1984) American Journal of Epidemiology 120:834-851. Yoshikawa et al. (1986) Jpn. J. Cancer Res. 77:1122-1133. Sternet al. (1993) Diabetes 42:706-714. Zweig et al. (1992) Clinical Chemistry 38: 1425-1428. U.S. Patent May 31, 2011 Sheet 1 of 23 US 7,951,382 B2 #7TW10dSTELLVEID?ZI | I’50IJI 07 G| to n n n n U.S. Patent May 31, 2011 Sheet 7 of 23 US 7,951,382 B2 U.S. Patent May 31, 2011 Sheet 8 of 23 US 7,951,382 B2 U.S. Patent May 31, 2011 Sheet 9 of 23 US 7,951,382 B2 E - Name van U.S. Patent OSHO U.S. Patent May 31, 2011 Sheet 12 of 23 US 7,951,382 B2 $$$98 ECp) 0I(5)IAI 8p) ]]NWISISJ?DO NOISS}\!908d,! C790 Z9e cioS ZEp (7. 9W OeudiaS y) I Lyuds IdnN 958 SNWHOOTO U.S. Patent May 31, 2011 Sheet 13 of 23 US 7,951,382 B2 Q.) VII'9IJI |WIJTS U.S. Patent May 31, 2011 Sheet 14 of 23 US 7,951,382 B2 |-,··\, HIMNS), U.S. Patent ~$100·| U.S. Patent May 31, 2011 Sheet 16 of 23 US 7,951,382 B2 S d40 U.S. Patent May 31, 2011 Sheet 17 Of 23 US 7,951,382 B2 U.S. Patent May 31, 2011 Sheet 18 of 23 US 7,951,382 B2 (O3I’50IJI |WHISMSINHINETd|N|00 U.S. Patent May 31, 2011 Sheet 19 Of 23 US 7,951,382 B2 CIZI‘50IJI U.S. Patent May 31, 2011 Sheet 20 of 23 US 7,951,382 B2 £I’9IJI U.S. Patent May 31, 2011 Sheet 21 of 23 US 7,951,382 B2 n a ts O as ers S =2 to N a 25 1d a 9go w O r1. o ere S. S. n O C se s o o (or o s s essa (%). SI-8VIO U.S. Patent May 31, 2011 Sheet 22 of 23 US 7,951,382 B2 U.S. Patent May 31, 2011 Sheet 23 of 23 US 7,951,382 B2 ZIS–E– 9I’50IJI 009 (IP/ful) 3A SOON19 OOOTS US 7,951,382 B2 1. 2 METHODS FOR TREATMENT OF TYPE 2 resistance to insulin uptake. Diabetes can also comprise DABETES abnormalities of carbohydrate, fat, and protein metabolism attributed to the deficient action of insulin on target tissues CROSS-REFERENCE TO RELATED resulting from insulin insensitivity or lack of insulin. APPLICATIONS 5 Type 2 Diabetes is the most common form of Diabetes, which typically develops as a result of a relative, rather than This application is a divisional of U.S. application Ser. No. absolute, insulin deficiency, in combination with the body’s 12/319,883, filed on Jan. 12, 2009 now abandoned, which is failure to use insulin properly (also known in the art as “insu a continuation-in-part of U.S. application Ser. No. 1 1/901, lin resistance'). Type 2 Diabetes often manifests in persons, 925, filed on Sep. 18, 2007 now abandoned, which is a con including children, who are overweight; other risk factors tinuation-in-part of International Application No. PCT/ include high cholesterol, high blood pressure, ethnicity, and US2007/007875, filed on Mar. 28, 2007, which claims benefit genetic factors, such as a family history of Diabetes. The of U.S. Provisional Application Ser. No. 60/841,717, filed on majority of patients with Type 2 Diabetes are obese, and Sep.
Details
-
File Typepdf
-
Upload Time-
-
Content LanguagesEnglish
-
Upload UserAnonymous/Not logged-in
-
File Pages85 Page
-
File Size-